



smpc for
LEVOFLOXACIN TABLE

S

**A
R
A
C
T
I
V
I
T
Y
T
E
S
T
S
(
S
M
P
C
)
T
E
S
T
I
N
G
M
E
T
H
O
D
S
O
F
T
W
A
R
E
P
R
O
D
U
C
T
I
O
N
S
O
F
T
W
A
R
E
P
R
O
D
U
C
T
I
O
N
S
O
F
T
W
A
R
E
P
R
O
D
U
C
T
I
O
N
S**

*are from the World
Health
Organisation
Public Assessment
Report WHOPAR
guidelines.]*

**M
P
L
A
T
E**

[Additional
instructions and
examples]

{<example text>}

*[
I
n
s
t
r
u
c
t
i
o
n
s
i
n
t
h
i
s
f
o
r
m
a
t
e
r
i
a
l*

**1. NAME OF
THE
MEDICINA
L
PRODUCT
EVAXIN**

**LEVOFLOXACI
N TABLETS
U.S.P. 500 MG.**

**2. QUALITATI
VE AND
QUANTITAT
IVE
COMPOSITI
ON**

Each Film coated
tablet contains:
Levofloxacin
Hemihydrate U.S.P.
Equivalent to
Levofloxacin 500 mg.
Excipients Q.S.
Colour: Red Iron
Oxide & Yellow Iron
Oxide

No gain the average
 te: weight.

Sr. No	Name of Raw Material	Sp ec	Label claim / tab	Qty per tablet (mg)	% Over age	Qty per tablet with Overages	Std. Qty for 1.0 Lac
1.	* Levofloxacin Hemihydrate Eq. to Levofloxacin 500 mg	USP	512 MG	512.00 MG	0 %	512.00 MG	51.20 KG
2.	** Microcrystalline cellulose	BP		75.53 MG	2 %	77.04 MG	7.704 KG
3.	** Maize Starch	BP		39.47 MG	8 %	42.630 MG	4.263 KG
4.	Sodium Benzoate	BP		1.00 MG		1.00 MG	0.100 KG
5.	Maize Starch (F/P)	BP		20.00 MG		20.00 MG	2.00 KG
	Purified water	BP					Q.S.
6.	Purified Talc	BP		7.00 MG		7.00 MG	0.700 KG
7.	Magnesium stearate	BP		7.00 MG		7.00 MG	0.700 KG
8.	Sodium Starch Glycollate	BP		10.00 MG		10.00 MG	1.000 KG
9.	Croscarmellose sodium	BP		21.00 MG		21.00 MG	2.100 KG
10.	Colloidal silicon dioxide	BP		7.00 MG		7.00 MG	0.700 KG
	Avg. wt of tablet		Total	700 MG		700.0 MG	70.00 KG

*

**

Co comp en sat e the qty of Act ive s wit h ma ize sta rch to ma int
 compen sate of overage s of microcr ystallin e cellulose and maize starch to loss on drying.

4.0 (A)
 COATING
 MATERIAL
 FORMULA:

SR. NO	NAME OF PACKING MATERIAL.	QTY PER BATCH.	UNIT
--------	---------------------------	----------------	------

1	coloured tablet ISO PROPYL ALCOHOL BP	2.100	LTR
2	shaped Ready mix of pure coat aqua Red IHS	1.400	KG
4	Big review Film BP Purified water BP	9.100	LTR

coated tablet

with GHL

Embossing.

P Clinical

H particulars

A

R

M

A

C

E

U

T

I

C

A

L

F

O

R

M

:

A

R

e

d

d

i

s

h

B

r

o

w

n

44.

Clinical particulars

4.1 Therapeutic indications

Levofloxacin Tablets is indicated in adults for the treatment of the following infections

- Acute bacterial sinusitis
- Acute exacerbations of chronic bronchitis
- Community-acquired pneumonia
- Complicated skin and soft tissue infections

For the above-mentioned infections Levofloxacin Tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.

- Pyelonephritis and complicated urinary tract infections
- Chronic bacterial prostatitis
- Uncomplicated cystitis
- Inhalation Anthrax: post-exposure prophylaxis and curative treatment

Levofloxacin Tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Levofloxacin Tablets are administered once or twice daily. The dosage depends on the type and severity of the

infection and the sensitivity of the presumed causative pathogen. Treatment time The duration of therapy varies according to the course of the disease. As with antibiotic therapy in general, administration of Levofloxacin Tablets should be continued for a minimum of 48 to 72 hours after the patient has become afebrile or evidence of bacterial eradication has been obtained. The following dose recommendations can be given for Levofloxacin Tablets: Dosage in patients with normal renal function (creatinine clearance > 50 ml/min)

Indication	Daily dose regimen (according to severity)	Duration of treatment (according to severity)
Acute bacterial prostatitis	500 mg once daily	10 - 14 days
Acute bacterial exacerbations of chronic bronchitis	500 mg once daily	7 - 10 days
Community-acquired pneumonia	500 mg once or twice daily	7 - 14 days
Pyelonephritis	500 mg once daily	7 - 10 days
Complicated urinary tract infections	500 mg once daily	7 - 14 days
Uncomplicated cystitis	250 mg once daily	3 days
Chronic bacterial prostatitis	400 mg once daily	28 days
Complicated skin and soft tissue infections	500 mg once or twice daily	7 - 14 days
Inhalation Anthrax	500 mg once daily	8 weeks

No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).

Impaired liver function

No adjustment of dosage is required since levofloxacin is not metabolised to any relevant extent by the liver and is mainly excreted by the kidneys. Elderly population No adjustment of dosage is required in the elderly, other than that imposed by consideration of renal function

Paediatric population

Levofloxacin is contraindicated in children and growing adolescents

Method of administration

For oral administration

Levofloxacin Tablets should be swallowed without crushing and with sufficient amount of liquid. They may be divided at the score line to adapt the dose. The tablets may be taken during meals or between meals.

Levofloxacin Tablets should be taken at least two hours before or after iron salts, zinc salts, magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents), and sucralfate administration since reduction of absorption can occur

-
-

4.3 Contraindications

Levofloxacin Tablets must not be used:

In patients hypersensitive to levofloxacin or other quinolones or to any of the excipients listed.

In patients with epilepsy,

In patients with history of tendon disorders related to fluoroquinolone administration,

In children or growing adolescents

- During pregnancy,
- In breast-feeding women.

4.4 Special warnings and precautions for use

Methicillin-resistant *Staphylococcus aureus* (MRSA)

Methicillin-resistant *S. aureus* are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore, levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate). Levofloxacin may be used in the treatment of Acute Bacterial Sinusitis and Acute Exacerbation of Chronic Bronchitis when these infections have been adequately diagnosed. Resistance to fluoroquinolones of *E. coli* – the most common pathogen involved in urinary tract infections – varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in *E. coli* to fluoroquinolones. Inhalation Anthrax: Use in humans is based on *in vitro* *Bacillus anthracis* susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.

Tendinitis and tendon rupture

Tendinitis may rarely occur. It most frequently involves the Achilles tendon and may lead to tendon rupture. Tendinitis and tendon rupture, sometimes bilateral, may occur within 48 hours of starting treatment with levofloxacin and have been reported up to several months after discontinuation of treatment. The risk of tendinitis and tendon rupture is increased in patients aged over 60 years, in patients receiving daily doses of 1000 mg and in patients using corticosteroids. The daily dose should be adjusted in elderly patients based on creatinine clearance. Close monitoring of these patients is therefore necessary if they are prescribed Levofloxacin. All patients should consult their physician if they experience symptoms of tendinitis. If tendinitis is suspected, treatment with Levofloxacin must be halted immediately, and appropriate treatment (e.g. immobilisation) must be initiated for the affected tendon.

Clostridium difficile-associated disease

Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with Levofloxacin (including several weeks after treatment), may be symptomatic of *Clostridium difficile*-associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudomembranous colitis. It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, Levofloxacin Tablets should be stopped immediately and appropriate treatment initiated without delay (e.g. oral metronidazole or vancomycin). Medicinal products inhibiting the peristalsis are contraindicated in this clinical situation.

Patients predisposed to seizures

Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures, or concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline. In case of convulsive seizures, treatment with levofloxacin should be

discontinued.

Patients with G-6- phosphate dehydrogenase deficiency

Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.

QT interval prolongation

Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example: - congenital long QT syndrome -concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics). - uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia) - cardiac disease (e.g. heart failure, myocardial infarction, bradycardia) Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations.

Peripheral neuropathy

Sensory or sensorimotor peripheral neuropathy has been reported in patients receiving fluoroquinolones, including levofloxacin, which can be rapid in its onset. Levofloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.

Hepatobiliary disorders

Cases of hepatic necrosis up to fatal hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis. Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.

Exacerbation of myasthenia gravis

Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis. Vision disorders If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.

4.5 Interaction with other medicinal products and other forms of interaction

Effect of other medicinal products on levofloxacin

Iron salts, zinc salts, magnesium- or aluminium-containing antacids, didanosine Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) are administered

concomitantly with Levofloxacin Tablets. Concurrent administration of fluoroquinolones with multi-vitamins containing zinc appears to reduce their oral absorption. It is recommended that preparations containing divalent or trivalent cations such as iron salts, zinc salts or magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) should not be taken 2 hours before or after Levofloxacin Tablets administration. Calcium salts have a minimal effect on the oral absorption of levofloxacin.

Sucralfate

The bioavailability of Levofloxacin Tablets is significantly reduced when administered together with sucralfate. If the patient is to receive both sucralfate and Levofloxacin Tablets, it is best to administer sucralfate 2 hours after the Levofloxacin Tablets administration.

Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs

No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However, a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold. Levofloxacin concentrations were about 13 % higher in the presence of fenbufen than when administered alone.

Vitamin K antagonists

Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists. Drugs known to prolong the QT interval Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotic). Other relevant information In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.

Other forms of interactions

Meals

There is no clinically relevant interaction with food. Levofloxacin Tablets may therefore be administered regardless of food intake

4.6 Pregnancy and Lactation

Pregnancy

There is limited amount of data with respect to the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. However, in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women.

Breast-feeding

Levofloxacin tablets are contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk; however other fluoroquinolones are excreted in breast milk. In the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism; levofloxacin must not be used in breast-feeding women.

Fertility

Levofloxacin caused no impairment of fertility or reproductive performance in rats.

4.7 Effects on ability to drive and use machines

Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient's ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).

4.8 Undesirable effects

The information given below is based on data from clinical studies in more than 8300 patients and on extensive post marketing experience. Frequencies are defined using the following convention: very common ($\geq 1/10$), common ($\geq 1/100$, $< 1/10$), uncommon ($\geq 1/1,000$, $< 1/100$), rare ($\geq 1/10,000$, $< 1/1,000$), very rare ($< 1/10,000$), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

	Common $\geq 1/100$ to $< 1/10$	Uncommon $\geq 1/1,000$ to $<$ $1/100$	Rare $\geq 1/10,000$ to $< 1/1,000$	Frequency not known (cannot be estimated from the available data)
Infections & Infestations		Fungal infection including Candida infection		cannot be estimated from the available data
Blood and Lymphatic System Disorders		Pathogen resistance Leukopenia Eosinophilia	Neutropenia Thrombocytopenia	Haemolytic anaemia Pancytopenia (life-threatening)
Immune System Disorders			Angioedema Hypersensitivity	Anaphylactic reaction Anaphylactic shock
Metabolism and Nutrition Disorders		Anorexia	Hypoglycaemia Particularly in diabetic Patients	Hyperglycaemia Hypoglycaemia coma
Psychiatric Disorders	Insomnia	Anxiety Confusional state Nervousness	Psychotic reactions (with e.g. hallucination, paranoia) Depression Agitation Abnormal dreams NIGHTMARES	Psychotic disorders with self-endangering behaviour including suicidal ideation or suicide attempt

Nervous System Disorders	Headache Dizziness	Somnolence Tremor Dysgeusia	Convulsion Paraesthesia	Peripheral sensory neuropathy Peripheral sensory motor neuropathy Parosmia including anosmia Dyskinesia Extrapyramidal disorder Ageusia Syncope Benign intracranial hypertension
Eye Disorders			Visual disturbances such as blurred vision	Transient vision loss

5.2 Pharmacokinetic properties

Absorption

Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1-2 h. The absolute bioavailability is 99-100%. Food has little effect on the absorption of levofloxacin. Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.

Distribution

Approximately 30-40% of levofloxacin is bound to serum protein. The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues. Penetration into tissues and body fluids: Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration into cerebro-spinal fluid.

Biotransformation

Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for < 5% of the dose excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.

Elimination

Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma ($t_{1/2}$: 6-8 h). Excretion is primarily by the renal route (> 85% of the administered dose). The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/- 29.2 ml/min. There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable. Linearity Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.

Special Populations

Elderly subjects There are no significant differences in levofloxacin kinetics between young and elderly subjects, except those associated with differences in creatinine clearance.

Gender differences

Separate analysis for male and female subjects showed small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development. Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on fetuses was delayed maturation as a result of maternal toxicity. Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells in vitro. These effects can be attributed to inhibition of topoisomerase II. In vivo tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.

Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenicity study. In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Microcrystalline Cellulose

Maize starch

Magnesium stearate BP

croscarmellose sodium

Sodium benzoate

Purified Water BP

talc

Colloidal Silicon Dioxide

Sodium starch glycolate

Coating Ingredients

Isopropyl alcohol

Ready mix of pure coat aqua red

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Store at a temperature not exceeding 30°C in a cool & dry place, Protect from light

6.5 Nature and contents of container <and special equipment for use, administration or implantation>

Alu – Alu Blister pack of 1 x 10 Tablets in a mono-carton along with pack insert

6.6 Special precautions for disposal <and other handling>

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. 7 MARKETING AUTHORISATION HOLDER
GLOBAL HEALTHCARE LIMITED**

#3,ADE-AKINSANYA STREET,

Off Town Planning Way, Lagos, Nigeria.

8. Marketing Authorization Number (s):

Product license / registration Number (s)

9. Manufacturer Name:

RELAX BIOTECH PVT. LTD.

862/1, G.I.D.C., Makarpura,

Vadodara-390010. Gujarat, India,

10- Date of first authorization/renewal of the authorization:

11- Date of revision of the text:
